Corrigendum to “Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway” [Cancer Letters 364 (2015) 79–88, (S0304383515003067), (10.1016/j.canlet.2015.04.027)];Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway

Cancer Letters

Volumn 364, Issue 1, 2015, Pages 79-88

  Xiang, Tong ^a,b   Du, Lanying ^a   Pham, Petra ^a   Zhu, Bo ^b   Jiang, Shibo ^a,c  

^a NEW YORK BLOOD CENTER   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cervical cancer; HIV protease inhibitor; Nelfinavir

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; MANGANESE SUPEROXIDE DISMUTASE; NELFINAVIR; REACTIVE OXYGEN METABOLITE; RITONAVIR; SAQUINAVIR; SUPEROXIDE DISMUTASE; TIPRANAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; UTERINE CERVIX CANCER; ANIMAL; CELL CYCLE; DRUG EFFECTS; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; NELFINAVIR; REACTIVE OXYGEN SPECIES; UTERINE CERVICAL NEOPLASMS;

EID: 84929655210     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2022.215895     Document Type: Erratum

References (47)

1. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med 2003, 348:518-527.
2. Vidya Priyadarsini R., Senthil Murugan R., Maitreyi S., Ramalingam K., Karunagaran D., Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kappaB inhibition. Eur. J. Pharmacol 2010, 649:84-91.
3. Eifel P.J., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J. Clin. Oncol 2004, 22:872-880.
4. Florea A.M., Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3(1):1351-1371.
5. Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. Cardiac side-effects of cancer chemotherapy. Int. J. Cardiol 2010, 144(1):3-15.
6. Monini P., Sgadari C., Toschi E., Barillari G., Ensoli B. Antitumour effects of antiretroviral therapy. Nat. Rev. Cancer 2004, 4(11):861-875.
7. Krischer J., Rutschmann O., Hirschel B., Vollenweider-Roten S., Saurat J.H., Pechère M. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J. Am. Acad. Dermatol 1998, 38(4):594-598.
8. Piccinini M., Rinaudo M.T., Anselmino A., et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther 2005, 10(2):215-223.
9. Yang Y., Ikezoe T., Nishioka C., et al. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br. J. Cancer 2006, 95(12):1653-1662.
10. Srirangam A., Mitra R., Wang M., et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin. Cancer Res 2006, 12(6):1883-1896.
11. Pajonk F., Himmelsbach J., Riess K., Sommer A., McBride W.H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002, 62(18):5230-5235.
12. Ikezoe T., Saito T., Bandobashi K., Yang Y., Koeffler H.P., Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol. Cancer Ther 2004, 3(4):473-479.
13. Jiang W., Mikochik P.J., Ra J.H., Lei H., Flaherty K.T., Winkler J.D., et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007, 67(3):1221-1227.
14. Kumar S., Bryant C.S., Chamala S., et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol. Cancer 2009, 8:26.
15. Barillari G., Iovane A., Bacigalupo I., et al. Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. AIDS 2012, 26(8):909-919.
16. Kappelmann M., Kuphal S., Meister G., Vardimon L., Bosserhoff A.K. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun proteinexpression. Oncogene 2013, 32(24):2984-2991.
17. Kyriazis A.P., Kyriazis A.A., Scarpelli D.G., Fogh J., Rao M.S., Lepera R. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am. J. Pathol 1982, 106(2):250-260.
18. Gupta S.C., Kim J.H., Prasad S., Aggarwal B.B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010, 29(3):405-434.
19. - current in cardiac myocytes via mitochondrial ROS. J. Mol. Cell. Cardiol 2010, 49(5):746-752.
20. Yu S.W., Wang H., Poitras M.F. Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297(5579):259-263.
21. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18(11):1272-1282.
22. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin. Cancer Res 2007, 13(3):789-794.
23. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 2003, 8(2):115-128.
24. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120(4):483-495.
25. Celotto A.M., Liu Z., Vandemark A.P., Palladino M.J. A novel Drosophila SOD2 mutant demonstrates a role for mitochondrial ROS in neurodevelopment and disease. Brain Behav 2012, 2(4):424-434.
26. Aarnoutse R.E., Droste J.A., van Oosterhout J.J., et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br. J. Clin. Pharmacol 2003, 55(2):115-125.
27. Gaedicke S., Firat-Geier E., Constantiniu O., Lucchiari-Hartz M., Freudenberg M., Galanos C., et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002, 62(23):6901-6908.
28. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol 2008, 26(16):2699-2706.
29. Ford J., Meaden E.R., Hoggard P.G., Dalton M., Newton P., Williams I., et al. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J. Antimicrob. Chemother 2003, 52(3):354-358.
30. Gills J.J., Lopiccolo J., Tsurutani J., et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res 2007, 13(17):5183-5194.
31. Yang Y., Ikezoe T., Takeuchi T., et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005, 96(7):425-433.
32. Guan M., Fousek K., Chow W.A. Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer. FEBS J. 2012, 279(13):2399-2411.
33. Conklin K.A. Cancer chemotherapy and antioxidants. J. Nutr 2004, 134(11):3201S-3204S.
34. Conklin K.A. Dietary polyunsaturated fatty acids: impact on cancer chemotherapy and radiation. Altern. Med. Rev 2002, 7(1):4-21.
35. Bruning A., Vogel M., Mylonas I., Friese K., Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr. Cancer Drug Targets 2011, 11(7):799-809.
36. Lin H.K., Hu Y.C., Lee D.K., Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol. Endocrinol 2004, 18(10):2409-2423.
37. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62(14):3893-3903.
38. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94(6):2102-2111.
39. Sturlan S., Baumgartner M., Roth E., Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003, 101(12):4990-4997.
40. Mahieux R., Pise-Masison C., Gessain A., et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98(13):3762-3769.
41. Candé C., Cecconi F., Dessen P., Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death?. J. Cell Sci 2002, 115(24):4727-4734.
42. Cregan S.P., Dawson V.L., Slack R.S. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004, 23(16):2785-2796.
43. Mondal D., Pradhan L., Ali M., Agrawal K.C. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc. Toxicol 2004, 4(3):287-302.
44. Lagathu C., Eustace B., Prot M., et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther 2007, 12(4):489-500.
45. Zhang S., Carper M.J., Lei X., Cade W.T., Yarasheski K.E., Ramanadham S. Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion. Am. J. Physiol. Endocrinol. Metab 2009, 296(4):925-935.
46. Jiang B., Hebert V.Y., Li Y., Mathis J.M., Alexander J.S., Dugas T.R. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol. Appl. Pharmacol 2007, 224(1):60-71.
47. Surabhi C., Debasis M., Krishna C.A. HIV-1 protease inhibitor induced oxidative stress in pancreatic beta-cells: protection with thymoquinone. Exp. Biol. Med. (Maywood) 2009, 234(4):442-453.